Human Papilloma Virus Infection Clinical Trial
Official title:
Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HPV HC2® Test in Women 30 Years of Age or Older Using LBC ThinPrep® Pap Test Specimens
To assess and compare the performance of the HR HPV HC2® test (Qiagen/Digene) and the APTIMA® HPV Assay (Hologic) using LBC Specimens (ThinPrep® Pap Test) for the detection of HPV infection and high-grade CIN lesions in a screening population of women 30 years of age or older in Germany.
The study is conducted in the areas of Tuebingen, Freiburg and Saarbruecken in Germany. In total, 10.000 ThinPrep® LBC cervical samples were collected from June 2009 to May 2012. Liquid based cytology (LBC) was performed by a central laboratory in Saarbruecken. Human papilloma virus (HPV) testing with the HR HPV HC2® test and APTIMA® HPV Assay were performed at the Section of Experimental Virology, Institute of Medical Virology, University Clinic of Tuebingen, Germany (UKT). Within a follow-up phase women who tested positive in any test at baseline will be monitored over a period of 10 years. Study close out visit: In addition, approximately 5 years after baseline ThinPrep® LBC cervical samples will be collected from a random sample of 4000 study participants who tested triple negative at baseline for determination of the longitudinal negative predictive value (NPV) and HPV related disease after a 5 year period. Women who tested positive in any test will undergo colposcopy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04199078 -
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
|
N/A | |
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02258659 -
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT02714114 -
Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)
|
N/A | |
Completed |
NCT00303823 -
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
|
Phase 2 | |
Not yet recruiting |
NCT05510830 -
Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
|
N/A | |
Completed |
NCT04002154 -
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
|
N/A | |
Not yet recruiting |
NCT06123533 -
Understanding Women's Values in Managing Human Papillomavirus (HPV)
|
||
Completed |
NCT04624568 -
Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance
|
N/A | |
Completed |
NCT05694728 -
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
|
Phase 2 | |
Completed |
NCT04391647 -
Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
|
||
Recruiting |
NCT05439083 -
Immunogenicity of 9-valent HPV Vaccine
|
Phase 4 | |
Completed |
NCT01446198 -
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHERâ„¢ System
|
N/A | |
Completed |
NCT01539668 -
Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas
|
Phase 0 | |
Recruiting |
NCT06467942 -
Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection
|
N/A | |
Completed |
NCT01567813 -
Post-Licensure Study of the Safety of GARDASILâ„¢ in Males (V501-070)
|
||
Completed |
NCT02811367 -
The HPV Self-test as a Test of Cure in Madagascar
|
N/A | |
Completed |
NCT02067507 -
Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County
|
N/A | |
Recruiting |
NCT01387997 -
e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses
|
N/A | |
Completed |
NCT00054041 -
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
|
Phase 2 |